key: cord-1023065-uipe62sc
authors: Peacock, Thomas P.; Sheppard, Carol M.; Brown, Jonathan C.; Goonawardane, Niluka; Zhou, Jie; Whiteley, Max; de Silva, Thushan I.; Barclay, Wendy S.
title: The SARS-CoV-2 variants associated with infections in India, B.1.617, show enhanced spike cleavage by furin
date: 2021-05-28
journal: bioRxiv
DOI: 10.1101/2021.05.28.446163
sha: ee82d736477ee4ac70332dd9e98b3f5ad3aa1f54
doc_id: 1023065
cord_uid: uipe62sc

The spike (S) glycoprotein of the SARS-CoV-2 virus that emerged in 2019 contained a suboptimal furin cleavage site at the S1/S2 junction with the sequence 681PRRAR/S686. This cleavage site is required for efficient airway replication, transmission, and pathogenicity of the virus. The B.1.617 lineage has recently emerged in India, coinciding with substantial disease burden across the country. Early evidence suggests that B.1.617.2 (a sublineage of B.1.617) is more highly transmissible than contemporary lineages. B.1.617 and its sublineages contain a constellation of S mutations including the substitution P681R predicted to further optimise this furin cleavage site. We provide experimental evidence that virus of the B.1.617 lineage has enhanced S cleavage, that enhanced processing of an expressed B.1.617 S protein in cells is due to P681R, and that this mutation enables more efficient cleavage of a peptide mimetic of the B.1.617 S1/S2 cleavage site by recombinant furin. Together, these data demonstrate viruses in this emerging lineage have enhanced S cleavage by furin which we hypothesise could be enhancing transmissibility and pathogenicity.

Unlike its closest known relatives, the SARS-CoV-2 spike (S) protein contains a furin cleavage 31 site at the S1/S2 junction that enhances SARS-CoV-2 replication in airway cells and contributes to virus 32 pathogenicity and transmissibility (1-6). Pre-cleavage of the S protein in producer cells allows CoV-2 to enter target cells at the cell surface avoiding endosomal restriction factors (4, 7). However, 34 the cleavage site of the early SARS-CoV-2 isolates that emerged in late 2019 are suboptimal, leaving 35 the potential for evolution of variants with increased transmission as a result of an optimised cleavage 36 site (4). 37

Towards the end of 2020 the SARS-CoV-2 pandemic entered a new phase with repeated 38 emergence of 'variants of concern' lineages with altered viral properties such as transmissibility, 39 pathogenicity, and antigenicity (8). The most widespread and best characterised of these variants is 40 the B.1.1.7 lineage, first found in the UK, which has increased transmissibility and pathogenicity compared to other circulating strains (9-11). We and others have previously described that the S1/S2 42 cleavage site of B.1.1.7 S contains a P681H mutation that enhances post-translational S1/S2 cleavage 43 during virus budding (12, 13 and associated with antigenic escape (see Table 1 ). One S substitution shared by all B.1.617 52 sublineages is P681R which we hypothesise further optimises the furin cleavage site (681PRRAR/S686 to 53 681RRRAR/S686, Figure 1a ). In this report we characterise the impact of P681R on the S1/S2 cleavage 54 site. 55

To investigate whether the S protein of B.1.617 undergoes a higher degree of post-57 translational cleavage at S1/S2 than previously circulating strains, we isolated several B.1.617 lineage 58 viruses (1 x B.1.617.1 and 2 x B.1.617.2) and compared their S1/S2 cleavage to that of a previously 59 circulating strain of lineage B.1.238, which contains only D614G. The B.1.617 lineage S proteins were 60 all more highly cleaved (≥50% cleaved), with a higher proportion of cleaved S2 and a lower proportion 61 of full-length S detectable than the control virus (~33% cleaved) (Figure 1b, c) . 62

To characterise which amino change in the B.1.617 S is responsible for its enhanced cleavage, 63 we generated pseudovirus containing the SARS-CoV-2 full B.1.617.1 S and compared it to pseudovirus 64 with D614G spike (WT). As we had previously observed, SARS-CoV-2 spike expressed on pseudovirus cleaved (~80%) S, B.1.617.1 S showed significantly enhanced cleavage (~95%), with an almost 67 complete lack of full-length protein (Figure 1d ,e). P681R alone (on a D614G backbone) was sufficient 68 to convey this phenotype (~96% cleaved), with cleavage enhanced to a similar level as for a previously 69 described S protein carrying the fully optimised furin cleavage site from an H5N1 avian influenza virus 70 haemagglutinin (~97% cleaved) (4). This suggests P681R alone is responsible for the enhanced S 71 cleavage seen in the B.1.617 lineages viruses. 72

We then performed assays to determine whether the optimised cleavage site found in the 73 B.1.617 S enables better cleavage directly by furin. We measured the ability of recombinant furin to 74 cleave fluorescently labelled peptides corresponding to the S1/S2 cleavage site of SARS-CoV-2 testing 75 peptides containing 681P (WT), 681R, or a monobasic mutant (monoCS) whereby two of the arginines 76 are substituted to non-basic residues (see Figure 1a ) (4). As expected, monoCS was poorly cleaved by 77 recombinant furin compared to the WT peptide which was efficiently cleaved by furin as previously 78 described ( Figure 1f) (2). P681R significantly enhanced the ability of furin to cleave the peptide 79 confirming that the arginine substitution is responsible for the enhanced cleavage of the B.1.617 S 80

To conclude, we speculate that enhanced S1/S2 cleavage seen in B.1.617 and B.1.1.7 (which 82 contains P681H (12)) may be contributing to the enhanced transmissibility of these SARS-CoV-2 83 variants. As well as B.1.1.7 and B.1.617, several other emerging lineages contain mutations in the furin 84 cleavage site (8). We would advise that these lineages be kept under close monitoring for any early 85 evidence of more rapid transmission or higher pathogenesis. 86 

The B.1.617.1 plasmid was generated from a previously described codon-optimised SARS-103

CoV-2 spike plasmid (Wuhan-hu-1)(18), using the QuikChange Lightning Multi Site-Directed 104

Mutagenesis kit (Agilent). Pseudovirus was generated and concentrated as previously described (4). 105

All spike expression plasmids used in this study contain D614G and K1255*STOP (that results in 106 deletion of the C-terminal cytoplasmic tail of spike containing the endoplasmic retention signal, aka 107 the Δ19 spike truncation). 108

Virus or pseudovirus concentrates were lysed in 4x Laemmli buffer (Bio-rad) with 10% β-110 mercaptoethanol and run on SDS-PAGE gels. After semi-dry transfer onto nitrocellulose membrane, 111 samples were probed with mouse anti-p24 (abcam; ab9071), rabbit anti-SARS spike protein (NOVUS; 112 NB100-56578), or rabbit anti-SARS-CoV-2 nucleocapsid (SinoBiological; 40143-R019). Near infra-red 113

The peptide cleavage assay was adapted from the protocol by Jaimes et al (2, 19) . Briefly 118 fluoregenic peptides were synthesised (Cambridge research biochemicals) with the sequences 119 TNSPRRARSVA (WT), TNSRRRARSVA (P681R) and TNSPSLARSVA (monoCS) and, N-terminally 120 conjugated with the fluorophore 5-Carboxyfluorescein (FAM) and the C-terminal quencher 2,4-121

Each peptide was tested for its ability to be cleaved by recombinant furin (10 U/mL; NEB; 123 P8077) in a buffer of 100 mM HEPES, 0.5% Triton X-100, 1mM CaCl2, 1 mM β-mercaptoethanol, pH 124 7.5. Assays were performed in triplicate at 30 o C and fluorescence intensity was measured at 125 wavelengths of 485 and 540 nm every 1 minute for 1 hour using a FLUOstar Omega plate reader (BMG 126 Labtech). Vmax was then calculated. 127 

Cell entry mechanisms of SARS-CoV-140 2

Proteolytic Cleavage of the SARS-CoV-2 Spike Protein and 142 the Role of the Novel S1/S2 Site. iScience

A Multibasic Cleavage Site in the Spike Protein of 144 SARS-CoV-2 Is Essential for Infection of Human Lung Cells

The furin cleavage site in 146 the SARS-CoV-2 spike protein is required for transmission in ferrets

Furin Cleavage Site 148 Is Key to SARS-CoV-2 Pathogenesis

A genome-wide CRISPR screen identifies host 150 factors that regulate SARS-CoV-2 entry

The polybasic cleavage 152 site in the SARS-CoV-2 spike modulates viral sensitivity to Type I interferon and IFITM2

Increased hazard of 156 death in community-tested cases of SARS-CoV-2 Variant of Concern

Estimated 159 transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Preliminary genomic 161 characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike 162 mutations

Increased 164 transmission of SARS-CoV-2 lineage B.1.1.7 (VOC 2020212/01) is not accounted for by a replicative 165 advantage in primary airway cells or antibody escape

Functional evaluation of proteolytic 167 activation for the SARS-CoV-2 variant B.1.1.7: role of the P681H mutation

Circulating 170 SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

A plasmid 175 DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 research

CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice

A Fluorogenic Peptide Cleavage 181 Assay to Screen for Proteolytic Activity: Applications for coronavirus spike protein activation

was determined by comparing the size to ΔCS which is unable to be cleaved by furin as 203 previously described (4)

Cleavage of SARS-CoV-2 spike S1/S2 fluorogenic peptide mimetics by recombinant furin

All assays performed in technical triplicate 207 (N=3) with a representative repeat from three completely independent repeats (N=3) shown

Graph plotted as mean + Standard deviation. One-way ANOVA with multiple comparisons 209 against the WT plotted on the graph